Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative study of effect of valsartan 160mg treatment versus continuous positive airway pressure on arterial blood pressure in patients who have an obstructive sleep apnea syndrome and a weak or moderate hypertension.

Next Previous
Trial Profile

Comparative study of effect of valsartan 160mg treatment versus continuous positive airway pressure on arterial blood pressure in patients who have an obstructive sleep apnea syndrome and a weak or moderate hypertension.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valsartan (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms VALSAS

Most Recent Events

  • 03 Jun 2010 Results published in the American journal of respiratory and critical care medicine.
  • 16 May 2010 Results in 23 patients have been presented at the 106th International Conference of the American Thoracic Society.
  • 31 Oct 2009 Results in 25 patients were published as an abstract in the proceedings of the 75th Annual Meeting of the American College of Chest Physicians: Chest 2009, 31 Oct 2009.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top